Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a multifactorial, progressive neurodegenerative disorder with a poor prognosis, and thus, novel therapies for AD are certainly needed in a growing population of elderly patients or asymptomatic individuals, who are at risk for AD, worldwide. It has been established that some AD biomarkers such as amyloid-beta load in the brain, precede the onset of the disease, by approximately 20 years. Therefore, the therapy to prevent or effectively treat AD has to be initiated before the emergence of symptoms. A goal of this review is to present the results of recent clinical trials on monoclonal antibodies against amyloid beta, used for the treatment of AD and also to address some of the current challenges and emerging strategies to prevent AD. In recent trials, a monoclonal antibody, i.e. solanezumab has shown some beneficial cognitive effects among mild AD patients. Ongoing studies with gantenerumab and crenezumab will examine when exactly the AD treatment, aimed at modifying the disease course has to be started. This review was based on Medline database search for trials on passive anti-AD immunotherapy, for which the main timeframe was set from 2012 to 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 5×
“[2] CAP includes investigators from the Anti‑Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study, the DIAN‑TU, and the API, as well as representatives from the US Food and Drug Administration, the National Institute on Aging, the Alzheimer’s Association, and the Fidelity Biosciences Research Initiative.”
BackgroundMethodInfluentialHow to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“Indian Journal of Pharmacology ‐ Vol 48, Issue 6, December 2016 635 and about 10–15 years, until a new investigational agent can be approved to the market.[44] Under these circumstances, passive amyloid‐beta immunotherapy appears to be a reasonable option for the health‐care budget.”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 2×
“[8] According to the “amyloid cascade hypothesis” that has been a cornerstone of the AD etiology for the last 20 years, the amyloid‐beta deposition in the brain precipitates the formation of NFTs.[1,5,9] However, the precise way, in which the cerebral deposition of amyloid beta leads to the formation of NFTs still rem…”
BackgroundIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · cited 1×
“[6] Products of this reaction include two forms of the amyloid beta peptide: (1) A chain containing 40 amino acids (the main form), and (2) a chain containing 42 amino acids (amyloid beta 1–42).[7] The amyloid beta 1–42 is more prone to aggregate into fibrils, which are the main components of cerebral neurotoxic senil…”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 12×
“[40] Therefore, the APOE database, used in the GeneMatch program, will expedite recruitment of sufficiently large number of candidates in the early stages of AD.”
MethodInfluentialMonetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“[41] At present, the AD‐related expenses are projected to be close to 215 billion US dollars, and in the future (by 2040), they are estimated to increase to approximately 500 billion US dollars annually.[42] Of course, almost incalculable costs of caregiver burden including their physical, mental, emotional, and econo…”
BackgroundSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“[19,21] In a phase 2 clinical trial, the occurrence of amyloid‐related imaging abnormalities (ARIA) detected by magnetic resonance imaging (MRI) of the brain,[22] in particular, vasogenic edema among bapineuzumab‐treated mild to moderate AD patients (which was increased in apolipoprotein E epsilon 4 [APOE e4] carriers…”
BackgroundKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · cited 1×
“[5,10,13] Among diverse amyloid beta species, the oligomeric amyloid beta, and amyloid beta‐derived diffusible ligands (ADDLs) have been implicated in cognitive decline, according to recent evidence.[14] Moreover, some recent trials conducted in the patient population with familial[15] and sporadic AD[16] have reveale…”
Cited by
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Baghallab, I., Reyes-Ruiz, J. M., Abulnaja, K., Huwait, E., & Glabe, C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180582 · Cited by 95
“(A ) is one of the leading approaches for therapeutic development including both active vaccination by using A antigens and passive vaccination using the anti-A antibodies [2].”
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
“However, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU) trials with these drugs largely failed over time in producing any clinically significant outcome [32].”
Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304153353 · Cited by 30
Metadata
- Authors
- Rygiel, K.
- Venue
- Indian Journal of Pharmacology
- Publisher
- Medknow
- Published
- 2016
- Volume
- 48
- Issue
- 6
- Pages
- 629
- ISSN
- 0253-7613 (ISSN-L)
- OpenAlex
- W2558209914
- Cited by
- 73
- References
- 23
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. https://app.cochat.ai/papers/10.4103/0253-7613.194867
- The paper
- Rygiel, K. (2016). Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian Journal of Pharmacology. https://doi.org/10.4103/0253-7613.194867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.